Introduction
Drug-drug interactions (DDIs) are defined as a medication interferes with pharmacokinetic, pharmacodynamic, or pharmaceutical properties of another drug, resulting in an altered net effect of one or both drugs (1) . DDIs could be a significant cause of morbidity and mortality because they may result in enhancement of drug toxicity and decrease in therapeutic effects of drugs (2) (3) (4) . DDIs are of particular concern in oncology because anticancer drugs usually have a narrow therapeutic index and small changes in cytotoxic activity due to a DDI can have serious consequences (5) . For example, concurrent use of nonsteroidal anti-inflammatory drugs (NSAIDs) and methotrexate may result in an increased risk of methotrexate toxicity, and fatal cases have been reported (6, 7) . Dual CYP3A4 and CYP1A2 inhibitor ciprofloxacin may result in increased erlo-tinib exposure and even lead to death (8) . Patients receiving anti-cancer therapy are particularly vulnerable to DDIs because they often take numerous medications concurrently to manage their malignancy, toxicities, cancer-associated syndromes and other co-morbid illnesses. These multiple medications can increase the risk of DDIs markedly (9, 10) . However, very limited data are available for potential drug interactions associated with anticancer therapy. In Belgium, forty-one potential interactions involving an anticancer agent and considered to be clinically significant were identified among 25% of patients (11) . Overall, ~5% of patients taking oral anticancer agents in Singapore were exposed to≥1 potentially interacting drug combination (10) . An observational study using medical records and autopsy analysis showed that 4% of deaths among cancer patients were caused by chemotherapy itself, and serious drug-drug interactions were sometimes suspected (12) . To date, there was no relevant research data about DDIs involving anticancer agents in China. The Chinese people's liberation army general hospital is the largest comprehensive hospital in China, owning more than 4400 beds in all and more than 300 beds in oncology. Considering combination between antineoplastic drugs and antineoplastic drugs sometimes are unavoidable as standard treatment such as concurrent use of cisplatin and paclitaxel despite enhancement of drug toxicity for DDIs, the main purpose of this study was to survey the prevalence of potential DDIs between antineoplastic drugs and nonantineoplastic drugs and evaluate the risk factors associated with these DDIs in the largest comprehensive hospital in China.
Materials and Methods

Study subjects
All discharged patients in the Department of Oncology were collected from Jun to Dec in 2016 with the Hospital Information System of the Chinese people's Liberation Army General Hospital.
The study protocol was approved by the Medical Ethics Committee of the hospital.
Experimental protocol
The inclusion criteria were: patients who received at least one anti-cancer drug and one nonanticancer drug simultaneously during oncology department stay were considered eligible. Anticancer agents include all traditional anti-tumor agents and molecule-targeted agents, and administration route was defined as intravenous and oral administration route. For each patient included, we collected the following data from the electronic medical record: age, sex, medications administered concurrently for anti-cancer drugs and non-anti-cancer drugs, type of cancer, tumor stage, and number of medication orders. Micromedex solutions database was utilized to identify potential interactions administered simultaneously between anti-cancer drugs and non-anti-cancer drugs because it was recognized as one of the most useful resources for identifying potential clinical effects (13) . Micromedex classifies DDIs into 5 categories of severity: contraindicated, major, moderate, minor, and unknown. For this study, only contraindicated, major and moderate were selected because interactions of minor severity lack clinical significance. Definitions for severity and documentation of DDIs by Micromedex are shown in Table  1 . Regarding mechanism of action, DDIs were classified as either pharmacokinetics or pharmacodynamics. Pharmaceutical interactions were not investigated because they were beyond the scope of our study. Tumor stages are classified in the study as stage IV and prior to stage IV because patients with stage IV face more complex physical, psychological, social, and spiritual consequences of disease and more treatment including disease-directed therapy, symptom management, and attention to quality of life compared with prior to stage IV (14) (15) (16) (17) .
Statistical analysis
We used descriptive statistics to summarize patient and potential drug interactions characteristics. Continuous variables were reported as mean±standard deviation (SD). The data were analyzed using independent sample t-test and chisquare test to compare the characteristic differences including age, sex, type of cancer, tumor stage and number of medication orders between patients with and without DDIs. Multiple logistic regression analysis was used to identify the factors from the statistically significant single factors. Data were analyzed using statistical software SPSS version 13.0 (Chicago, IL, USA) with test level α=0.05. P-values less than 0.05 were considered statistically significant.
Results
From Jun to Dec in 2016, 6578 patients who received at least one anti-cancer drug and one nonanti-cancer drug simultaneously were identified. The characteristics of the 6578 eligible patients were summarized in Table 2 . Table 3) .
The most common drug-drug interactions are summarized in Table 4 . However, no significant differences were found in sex. Results of the multiple logistic regression analysis are presented in Table 6 . 
Discussion
Overall, 1830 out of 6578 (27.82%) patients receiving antineoplastic therapy are exposed to at least one potential DDI. The prevalence observed in the study was comparable to the study of Belgium, 25% of patients were exposed to clinically significant DDIs (11) . Considering high risk associated with DDIs in cancer patients, and almost all DDIs (97.02%) were classified as major, more attention should be paid by oncologists. Among the identified DDIs, the largest number of drug-drug interaction was cisplatin and furosemide. Furosemide is commonly used to mitigate nephrotoxicity of cisplatin. However, the protective effect of furosemide against nephrotoxicity has not been confirmed (18) . In fact, furosemide enhanced nephrotoxicity of cisplatin (19) (20) (21) (22) . Twenty-six mg median dose of furosemide was associated with cisplatin nephrotoxicity and an explanation is that furosemide may have a direct toxic effect on the kidney (19) . Furosemide-induced GFR reduction (20) . Highdose furosemide leads to proximal tubular necrosis and its use with cisplatin may aggravate the nephrotoxicity (21, 22) . In addition, furosemide causes edema of the stria vascularis, disrupts the blood-ear barrier, and enhances the entry of ototoxic drugs into the inner ear, known to potentiate cisplatin-induced hearing loss (23) (24) (25) . Therefore, many researchers have sought less toxic methods for administering cisplatin without furosemide (26, 27) . The second most frequent DDI detected in our study was pemetrexed and NSAIDs, mainly found in patients with lung adenocarcinoma with bone metastasis or pain. Severe hematologic toxicities in patients receiving carboplatin-based pemetrexed may be significantly induced by the inhibition of renal tubular secretion of pemetrexed through drug-drug interactions between NSAIDs and pemetrexed (28) . Renal dysfunction may easily develop as a result of continued pemetrexed administration combined with NSAID therapy (29) . Therefore, it is necessary to take precautions against adverse side effects when combining pemetrexed with NSAID therapy. Erlotinib was most likely to interact with various non-anticancer drugs including PPI, rifampicin, warfarin, and carbamazepine. Erlotinib is a tyrosine kinase inhibitor, which drug interactions occur commonly because of DDIs concern absorption (incomplete drug absorption is a risk of drug interaction) and metabolization by the cytochrome P450 isozymes (30) . Significant clinical consequences have been associated with these interaction mechanisms (8, 31, 32) . Interaction between sunitinib and ondansetron or quinolones was found in the study which may result in an increased risk of QT interval prolongation. Similar risk of interaction involved sorafenib and ondansetron. Medical oncologists should be better known about the risk of increased tyrosine kinase inhibitor toxicity or decreased tyrosine kinase inhibitor efficacy in patients given tyrosine-kinase inhibitors. If possible, the combination of some tyrosine-kinase in-hibitors and proton-pump inhibitor should be avoided. Dose adjustments of tyrosine-kinase inhibitors are highly recommended when combined with strong CYP3A4 inhibitors or inducers which can significantly affect the exposure to tyrosine-kinase inhibitors. Unless absolutely necessary, coadministration QTc-prolonging tyrosinekinase inhibitors and drugs that prolong the QTc interval should be avoided (30) . Our study revealed that patients taking more medications, those with stage IV and lung cancer patients were at greater risk of drug interactions. Patients with lung cancer were almost 5 times more likely to be exposed to drug interactions than patients with gastric cancer. The finding of Holland researchers was similar to ours. Lung cancer patients have a high risk of drug-drug interactions (33) . Cisplatin, TKI, and pemetrexed which often used by lung cancer patients have a high number of DDIs. Conversely, compared with gastric cancer patients, breast and intestinal patients were only 0.73 and 0.05 times to be exposed to drug interactions. The result suggested breast and intestinal patients were at lower risk of drug interactions. Similar to other studies (9, 34) , the increasing number of medications was associated with more potential drug interactions in our study. Cancer patients with co-morbid illnesses or cancerassociated syndromes usually take more medications with potential drug-drug interactions. Patients with stage IV were also at increased risk of drug interactions because they face more treatment including disease-directed therapy, symptom management, and attention to quality of life compared with prior to stage IV. However, different from previous studies (9, 10, 35, 36) , older patients were not found to have an increased risk of DDI exposure in our study. Patients receiving chemotherapy usually need good or moderate performance status, no matter the older or the younger patients. The present study has several limitations. First, analysis data was only from one institution, so the result might be vulnerable to institution bias. Second, many patients were administered oral therapy such as tyrosine kinase inhibitors outside the hospital, which resulted in drug-drug interactions in patients receiving tyrosine kinase inhibitors were underestimated. And the data were not analyzed to compare the characteristic differences in antineoplastic category between patients with and without DDIs due to difficult evaluation, because many patients were administered simultaneously traditional anti-tumor agents and molecule-targeted agents. In addition, documentation evidence of majority of DDIs (86.21%) was classified as fair, suggesting the interactions need more available documentation and wellcontrolled studies.
Conclusion
Potential drug-drug interactions between antineoplastic drugs and non-antineoplastic drugs occur frequently in cancer patients of Chinese hospitals. Doctors should fully consider potential risk associated with DDIs. Further research should be performed to evaluate real clinical significance of these DDIs.
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